检索结果 - Tariq Abuali
- Showing 1 - 2 results of 2
-
1
-
2
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy 由 Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo, Maximilian Diehn, Summer S. Han, Heather A. Wakelee
出版 2021Artigo
相关主题
Cancer
Internal medicine
Medicine
Oncology
Adverse effect
Biochemistry
Biology
Biomarker
Cancer detection
Cancer screening
Chemistry
Chemoradiotherapy
Computed tomography
Disease
Durvalumab
Epidermal growth factor receptor
Erlotinib
Immunotherapy
Intensive care medicine
Lung
Lung cancer
Lung cancer screening
Medical physics
Molecular biomarkers
Multidisciplinary approach
Narrative review
Nivolumab
Osimertinib
Paleontology
Pathology